We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

Back to rankings

137 hedge funds and large institutions have $573M invested in Five Prime Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 31 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 31

58% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 19

9% more funds holding

Funds holding: 126 → 137 (+11)

41% less call options, than puts

Call options by funds: $2.14M | Put options by funds: $3.64M

43% less capital invested

Capital invested by funds: $1B → $573M (-$428M)

Holders
137
Holders Change
+11
Holders Change %
+8.73%
% of All Funds
3.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
52
Reduced
31
Closed
19
Calls
$2.14M
Puts
$3.64M
Net Calls
-$1.5M
Net Calls Change
-$597K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$23.6M
2
DM
Deerfield Management
New York
+$14.5M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$14.5M
4
Victory Capital Management
Victory Capital Management
Texas
+$12.6M
5
Morgan Stanley
Morgan Stanley
New York
+$9.6M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.4M
2
HM
HealthCor Management
New York
-$29.3M
3
EAM
Eventide Asset Management
Massachusetts
-$9.2M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$4.18M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$4.11M +$61.6K +1,915 +1%
DekaBank Deutsche Girozentrale
27
DekaBank Deutsche Girozentrale
Germany
$3.72M – – –
Goldman Sachs
28
Goldman Sachs
New York
$3.36M +$2.92M +90,810 +145%
ARTA
29
A.R.T. Advisors
New York
$3.34M +$4.09M +127,295 +510%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$3.29M -$2.42M -75,178 -33%
AIC
31
AWM Investment Company
New York
$3.29M +$1.61M +50,000 +50%
Two Sigma Investments
32
Two Sigma Investments
New York
$3.1M +$4.54M +141,268 New
Deutsche Bank
33
Deutsche Bank
Germany
$3.07M +$889K +27,655 +25%
Axa
34
Axa
France
$2.91M -$4.44K -138 -0.1%
Charles Schwab
35
Charles Schwab
California
$2.84M -$355K -11,044 -8%
IBT
36
International Biotechnology Trust
United Kingdom
$2.53M +$933K +29,000 +34%
HM
37
HealthCor Management
New York
$2.21M -$29.3M -909,930 -90%
RI
38
RTW Investments
New York
$2.2M +$3.23M +100,377 New
UBS AM
39
UBS AM
Illinois
$2.12M -$348K -10,832 -10%
Citadel Advisors
40
Citadel Advisors
Florida
$1.83M +$2.68M +83,284 New
CS
41
Candriam SCA
Luxembourg
$1.75M +$965K +30,000 +60%
GPCM
42
Granite Point Capital Management
Massachusetts
$1.75M +$965K +30,000 +60%
AGA
43
Altrinsic Global Advisors
Connecticut
$1.75M +$2.57M +80,000 New
Citigroup
44
Citigroup
New York
$1.55M +$1.45M +45,035 +176%
TCIM
45
TIAA CREF Investment Management
New York
$1.4M -$334K -10,378 -14%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$1.39M +$1.8M +56,100 +748%
PIM
47
Platinum Investment Management
Australia
$1.38M +$1.35M +42,000 +202%
VIA
48
Vident Investment Advisory
Georgia
$1.31M +$611K +18,994 +47%
TAM
49
Trillium Asset Management
Massachusetts
$1.29M -$190K -5,894 -9%
GC
50
Guggenheim Capital
Illinois
$1.28M -$326K -10,135 -15%
1
2
3 4 5

FPRX Hedge Fund Activity: Q4 2017 in Review

137 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2017, worth a combined $573M — down 43% from $1B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new FPRX positions and 19 closed out — a net gain of 11 holders — while 52 added to existing stakes and 31 trimmed.

The largest buyer was State Street, adding an estimated $23.6M. The largest seller was Adage Capital Partners, cutting an estimated $36.4M.

  • 137 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2017, up from 126 in Q3 2017.
  • Funds reported $573M of Five Prime Therapeutics, Inc. stock for Q4 2017, down 43% quarter-over-quarter.
  • 30 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2017 and 19 closed out, a net change of +11 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q4 2017 was State Street, an estimated $23.6M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q4 2017 was Adage Capital Partners, an estimated $36.4M sold.

Based on aggregated 13F filings for Q4 2017.